vs

Side-by-side financial comparison of Beneficient (BENF) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $18.7M, roughly 2.0× Beneficient). On growth, Beneficient posted the faster year-over-year revenue change (322.5% vs -57.1%).

Beneficient is a financial services firm specializing in alternative asset liquidity solutions. It offers tailored options for holders of illiquid alternative investments including private equity, hedge fund stakes, and real assets, serving institutional investors, high-net-worth individuals, and family offices primarily in North America.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

BENF vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
2.0× larger
ORGO
$37.2M
$18.7M
BENF
Growing faster (revenue YoY)
BENF
BENF
+379.6% gap
BENF
322.5%
-57.1%
ORGO

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
BENF
BENF
ORGO
ORGO
Revenue
$18.7M
$37.2M
Net Profit
$19.9M
Gross Margin
30.8%
Operating Margin
21.1%
-185.1%
Net Margin
106.7%
Revenue YoY
322.5%
-57.1%
Net Profit YoY
330.5%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BENF
BENF
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$18.7M
$225.6M
Q3 25
$-2.8M
$150.9M
Q2 25
$-12.6M
$101.0M
Q1 25
$-31.0M
$86.7M
Q4 24
$4.4M
$126.7M
Q3 24
$8.6M
$115.2M
Q2 24
$10.0M
$130.2M
Net Profit
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
$19.9M
$43.7M
Q3 25
$-17.9M
$21.6M
Q2 25
$-92.6M
$-9.4M
Q1 25
$-44.6M
$-18.8M
Q4 24
$-8.6M
$7.7M
Q3 24
$9.7M
$12.3M
Q2 24
$44.3M
$-17.0M
Gross Margin
BENF
BENF
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
BENF
BENF
ORGO
ORGO
Q1 26
-185.1%
Q4 25
21.1%
28.1%
Q3 25
646.5%
13.7%
Q2 25
734.0%
-12.5%
Q1 25
146.3%
-30.9%
Q4 24
-215.3%
8.1%
Q3 24
-160.2%
5.4%
Q2 24
-10.7%
Net Margin
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
106.7%
19.4%
Q3 25
648.1%
14.3%
Q2 25
734.0%
-9.3%
Q1 25
144.1%
-21.7%
Q4 24
-195.5%
6.1%
Q3 24
113.9%
10.7%
Q2 24
441.1%
-13.1%
EPS (diluted)
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
$0.31
Q3 25
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BENF
BENF
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$7.9M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$-128.6M
Total Assets
$337.9M
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BENF
BENF
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$7.9M
$93.7M
Q3 25
$4.9M
$63.7M
Q2 25
$7.6M
$73.1M
Q1 25
$1.3M
$110.0M
Q4 24
$4.1M
$135.6M
Q3 24
$4.5M
$94.3M
Q2 24
$4.4M
$89.9M
Total Debt
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
$-128.6M
$300.1M
Q3 25
$-142.8M
$255.1M
Q2 25
$-120.4M
$233.2M
Q1 25
$-34.9M
$242.9M
Q4 24
$14.3M
$262.9M
Q3 24
$-13.2M
$278.5M
Q2 24
$-148.3M
$263.5M
Total Assets
BENF
BENF
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$337.9M
$598.7M
Q3 25
$316.2M
$509.8M
Q2 25
$334.5M
$461.1M
Q1 25
$354.9M
$467.4M
Q4 24
$400.0M
$497.9M
Q3 24
$368.8M
$446.3M
Q2 24
$361.3M
$443.2M
Debt / Equity
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BENF
BENF
ORGO
ORGO
Operating Cash FlowLast quarter
$-9.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
-0.47×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
$-9.4M
$39.4M
Q3 25
$-14.5M
$3.1M
Q2 25
$-10.8M
$-32.9M
Q1 25
$-37.7M
$-19.9M
Q4 24
$-10.0M
$10.9M
Q3 24
$-8.6M
$8.7M
Q2 24
$-10.6M
$4.7M
Free Cash Flow
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-10.9M
$-36.5M
Q1 25
$-38.8M
$-23.6M
Q4 24
$-10.0M
$7.6M
Q3 24
$-8.9M
$6.1M
Q2 24
$-11.3M
$2.9M
FCF Margin
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
86.6%
-36.1%
Q1 25
125.3%
-27.2%
Q4 24
-227.2%
6.0%
Q3 24
-103.7%
5.3%
Q2 24
-112.6%
2.2%
Capex Intensity
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
0.0%
2.1%
Q3 25
0.0%
1.5%
Q2 25
-0.8%
3.6%
Q1 25
-3.5%
4.2%
Q4 24
1.0%
2.7%
Q3 24
3.1%
2.2%
Q2 24
6.6%
1.4%
Cash Conversion
BENF
BENF
ORGO
ORGO
Q1 26
Q4 25
-0.47×
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
-0.88×
0.71×
Q2 24
-0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BENF
BENF

Ben Liquidity$8.2M44%
Other$7.6M41%
Ben Custody$2.9M16%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons